Pod těmito názvy můžete látku najít v jiných zdrojích
RAXORULIMOGEN BELZOVACIREPVEC
RAXORULIMOGÉN BELZOVACIREPVEC
RECOMBINANT REPLICATION-COMPETENT ONCOLYTIC VACCINIA VIRUS (VACV; STRAIN COPENHAGEN) ENCODING THREE CODON-OPTIMISED TRANSGENES: (I) ANTI-CYTOTOXIC TLYMPHOCYTE- ASSOCIATED PROTEIN 4 (CTLA-4) IMMUNOGLOBULIN G1 GAMMA1-CHAIN FUSED VIA A SYNTHETIC T2A PEPTIDE WITH HUMAN IMMUNOGLOBULIN KAPPA CHAIN (ANTI- CTL4 ANTIBODY) UNDER CONTROL OF THE VACV H5R PROMOTER, (II) HUMAN FMS-LIKE RECEPTOR TYROSINE KINASE 3 LIGAND (FLT3L), ISOFORM X7, UNDER CONTROL OF THE VACV B19R PROMOTER, AND (III) MEMBRANE BOUND HUMAN INTERLEUKIN 12 SUBUNIT ALPHA (IL-12A, P35) UNDER CONTROL OF A SYNTHETIC VACV LATE PROMOTER (PLATE). THE VIRUS CARRIES MAJOR GENOMIC DELETIONS AT THE 5' END (COPMD5P) AND 3' END (COPMD3P) OF THE GENOME WITH THE ANTI-HCTLA-4 TRANSGENE INSERTED INTO THE COPMD5P REGION. IN ADDITION, INSERTION OF THE FLT3L AND IL-12P35 TRANSGENES LEADS TO DISRUPTION OF THE B8R LOCUS.